Recent literature has established benefits of DPP4 inhibitors on progression-free survival (PFS) of diabetic patients with advanced colorectal and airway cancers, as well as improved overall survival (OS) in colorectal and lung cancer [3,4]. The gene discussed is DPP4; the disease is lung cancer.